1. Introduction {#sec0001}
===============

Lung cancer is the most common cancer in men and the leading cancer-related death in women in most developed countries, which lead to an enormous burden on family and social [@bib0001]. Even if the technology of lung cancer screening have been growing for several years, the reduction in lung cancer mortality was not extremely lower than before [@bib0002]. Although the number of smokers has decreased significantly in recent years, lung cancer still remained high mortality accounting for nearly 27.4% of all cancer deaths and 5-year survival rates of lung cancer ranged from 4 to 17% for regional differences [@bib0003], [@bib0004]. Lung cancer incidence trends was significantly different by gender, race, sex and histology in different countries [@bib0005], [@bib0006], [@bib0007], [@bib0008], [@bib0009], [@bib0010].

Bone metastasis (BM) was one of the most common distant metastases in patients with lung cancer, which brought about poor prognosis as an incurable disease. Nearly 20% of lung cancer patients aged ≥65 years were diagnosed with BM [@bib0011]. BM in non-small cell lung cancer was predominant in different metastatic patterns, with a rate of 37.1% [@bib0012]. Although survival time for lung cancer patients has been increased through improving medical care, the risk of BM which resulted in poor prognosis remained increasing [@bib0013], [@bib0014], [@bib0015]. It was a great pity that there was not a standard and palliative management strategy to reduce the odds of BM and an assessment method for prognosis.

The purpose of this study is to use the Surveillance, Epidemiology, and End Results (SEER) to analyze the risk factors of BM and estimate prognosis for BM in patients diagnosed with lung cancer, as well as further analyze homogeneous and heterogeneous factors. Factors include age, race, histological type, marital status, T stage, N stage, grade classification, the tumor size, brain metastasis, and liver metastasis.

2. Methods {#sec0002}
==========

2.1. Study population {#sec0003}
---------------------

Lung and bronchus cancer cases were obtained from the National Cancer Institute\'s SEER program (<https://seer.cancer.gov>), which consisted of 18 population-based cancer registries. The SEER database collected and published cancer data covering nearly 28% of the total population in the United States. We send the data agreement to the SEER administration and accepted the agreement from the administrator. We had the right to obtain the information of patients with personal account. In the SEER database, all available data were retrospective, so Institutional Review Board approval was not required in our study.

Because this database began collecting the information on bone metastases at the time of diagnosis in 2010 and related information was updated until 2015, we extracted data on lung cancer patients with the presence or absence of BM at the time of diagnosis from 2010 to 2015. The data was selected and listed in flow-chart ([Fig. 1](#fig0001){ref-type="fig"}). In total, 9212 patients who were diagnosed as lung cancer with BM and 26,374 patients who were diagnosed as lung cancer without BM from 2010 to 2015 were selected. Subsequently, we removed patients with invalid information, leaving 8954 patients eligible for survival analysis and 25,631 patients eligible for multivariable logistic regression model.Fig. 1The flow-chart of the data selection for analyzing the risk factors of the morbidity and prognosis of bone metastasis from lung cancer patients**Abbreviations:** BM, bone metastasis.Fig 1

2.2. Statistical analysis {#sec0004}
-------------------------

Demographic data, including sex(male and female), age (≤40, 41--60, 61--80, and ≥81years), race \[white, black, American Indian/Alaska Native (AI) and Asian or Pacific Islander (API)\], marital status (married and unmarried), tumor sites (\< 2;≥2,\< 4; ≥4,\< 6;\>6,≤8;≥8,\< 10;≥10,\< 12;≥12,\< 14;≥14), grade(I,II,III,IV), T stage(T0,T1, T2, T3, and T4), N stage(N0,N1, N2 and N3), metastasis at brain(yes and no) and metastasis at liver(yes and no). In addition, the histology codes were grouped into five categories based largely on the International Agency for Research on Cancer (IARC) classifications [@bib0016]: adenocarcinoma (histologic codes 8140,8230,8244,8255,8260,8310,8323,8480,8481,8490,8507,8550,8570,8574,8576),squamous cell carcinoma (histologic code 8050,8070-8074,8123), large cell carcinoma(histologic codes 8012-8014,8020--8022,8030,8031), small cell carcinoma (8041-8045,8246) and others(8000-8004,8010,8032-8034,8046,8082,8200,8240,8241,8247,8249-8254,8342,8430,8560,8575,8980).

Multivariable logistic regression was used to show the odds ratios (ORs) with 95% confidence intervals (CIs) and distinguish the risk factors for developing BM at diagnosis. Kaplan-Meier method was used to analyze survival duration; Log-rank test were tested to distinguish the differences between the curves. Multivariable Cox proportional hazards regression was performed to show the hazard ratios (HRs) with 95% CIs and determine prognostic effects of every variable on survival.

All statistical analyses were performed using SPSS 22.0 (Chicago, IL, USA). Two-sided P-values \< 0.05 were considered significant statistically.

3. Results {#sec0005}
==========

3.1. Morbidity analysis {#sec0006}
-----------------------

For the 34,585 eligible lung cancer patients who were diagnosed with BM or without BM between 2010 and 2015 in the study, [Table 1](#tbl0001){ref-type="table"} shows the number of the two cohorts according to different variables in the SEER. Of them, 8954 (25.9%) were diagnosed with BM at the initial diagnosis and we had their complete information. Thus, they were included in the survival analysis, and their demographic and clinical characteristics were shown in [Table 2](#tbl0002){ref-type="table"}. Within this cohort, the median survival time was only 2 ± 0.12 months and the mean was just 6.61±0.26 months, while the time was 4 ± 0.16 months and 13.18±0.27 month for the patients without BM respectively.Table 1Multivariable logistic regression for analyzing the demographic information and risk factors for occurrence of bone metastasis in patients diagnosed lung cancer (diagnosed 2010--2015).Table 1Subject characteristicsNo. of patients with LCOR (95%CI)*P* valueWith bone metastasisWithout bone metastasis**Sex**\<0.001 Male516313,2531 (reference)1.000 Female379112,3780.804 (0.763--0.847)\<0.001**Age, in years**\<0.001 ≤40941881 (reference)1.000 41--60225450000.876 (0.670--1.145)0.331 61--80522114,7660.739 (0.567--0.963)0.025 ≥81138556770.536 (0.409--0.702)\<0.001**Race**0.004 Black100230021 (reference)1.000 White726520,8511.080 (0.995--1.171)0.066 AI461450.915 (0.637--1.314)0.631 API63115561.153 (1.016--1.307)0.027 Unknown1077NANA**Marital status**0.012 Married434311,5731 (reference)1.000 Unmarried416812,5540.953 (0.903--1.007)0.084 Unknown4431504NANA**Hist** AD414410,2351 (reference)1.000 SQCC83333190.629 (0.574--0.688)\<0.001 LCLC1664240.786 (0.646--0.956)0.016 SCLC176852200.544 (0.504--0.586)\<0.001 Other20436433NANA**Gleason grade**\<0.001 I906561 (reference)1.000 II34815281.456 (1.124--1.887)0.004 III120937601.778 (1.400--2.258)\<0.001 IV2307082.044 (1.542--2.710)\<0.001 Unknown707718,979NANA**tumor size(cm)**0.313 ≤279528051 (reference)1.000 \>2, ≤487429591.140 (0.989--1.315)0.071 \>4, ≤672321421.177 (1.010--1.373)0.037 \>6, ≤844913641.099 (0.929--1.300)0.270 \>8, ≤102457461.080 (0.887--1.314)0.444 \>10, ≤121223391.168 (0.909--1.501)0.225 \>12, ≤14311440.772 (0.506--1.177)0.229 \>14381300.935 (0.628--1.393)0.743 Unknown567715,002NANA**T Stage**\<0.001 T040012381 (reference)1.000 T120011290.685 (0.553--0.848)0.001 T286732040.836 (0.692--1.010)0.064 T3173641281.195 (0.999--1.429)0.051 T4246871581.021 (0.858--1.215)0.811 TX32838774NANA**N Stage**\<0.001 N0169574521 (reference)1.000 N161015041.544 (1.377--1.731)\<0.001 N2333890101.372 (1.279--1.472)\<0.001 N3171838431.605 (1.476--1.744)\<0.001 NX15933822NANA**Brain Met**\<0.001 Yes173333521 (reference)1.000 None667822,1010.708 (0.661--0.758)\<0.001 Unknown543178NANA**Liver Met**\<0.001 Yes298536171 (reference)1.000 None547321,8070.304 (0.286--0.323)\<0.001 Unknown496207NANA[^1]Table 2Multivariable Cox regression for analyzing prognostic factors among lung cancer patients diagnosed bone metastasis (diagnosed 2010--2015).Table 2Subject characteristicsNo. of patients with LC with bone metastasisSurvival, Median (IQR), moCox HR (95% CI)*P* value**Sex**\<0.001 Male51632 (1.848--2.152)1 (reference)1 Female37913 (2.823--3.177)0.883 (0.843--0.924)\<0.001**Age, in years**\<0.001 ≤40949 (5.101--12.899)1 (reference)1 41--6022544 (3.667--4.333)1.651 (1.297--2.100)\<0.001 61--8052212 (1.852--2.148)2.091 (1.647--2.655)\<0.001 ≥8113851 (0.846--1.154)2.701 (2.116--3.448)\<0.001**Race**\<0.001 Black10022 (1.672--2.328)1 (reference)1 White72652 (1.871--2.129)0.978 (0.912--1.050)0.544 AI462 (0.792--3.208)0.785 (0.567--1.087)0.145 API6313 (2.164--3.836)0.733 (0.656--0.819)\<0.001 Unknown10NANANA**Marital status**\<0.001 Married43433 (2.807--3.193)1 (reference)1 Unmarried41682 (1.839--2.161)1.196 (1.142--1.254)\<0.001 Unknown443NANANA**Hist**\<0.001 AD41443 (2.814--3.186)1 (reference)\<0.001 SQCC8332 (1.678--2.3221.170 (1.081--1.266)0.011 LCLC1662 (1.394--2.606)1.232 (1.050--1.466)0.024 SCLC17684 (3.560--4.440)0.929 (0.871--0.990)0.001 Other2043NANANA**Gleason grade**0.106 I904 (2.495--5.505)1 (reference)1 II3483 (2.236--3.764)1.257 (0.978--1.616)0.074 III12093 (2.713--3.287)1.342 (1.064--1.693)0.013 IV2303 (2.286--3.714)1.402 (1.076--1.827)0.012 Unknown7077NANANA**Tumor size (cm)**0.015 ≤27954 (3.449--4.551)1 (reference)1 \>2, ≤48743 (2.628--3.372)1.144 (1.007--1.301)0.039 \>4, ≤67233 (2.622--3.378)1.187 (1.036--1.360)0.013 \>6, ≤84492 (1.478--2.522)1.237 (1.066--1.436)0.005 \>8, ≤102453 (2.071--3.929)1.111 (0.932--1.324)0.239 \>10, ≤121221 (0.414--1.586)1.382 (1.114--1.716)0.003 \>12, ≤14312 (0.971--3.029)1.564 (1.053--2.322)0.027 \>14383 (0.448--5.552)1.318 (0.928--1.873)0.123 Unknown5677NANANA**T Stage**0.465 T04003 (2.247--3.753)1 (reference)1 T12004 (3.079--4.921)0.829 (0.678--1.013)0.067 T28673 (2.602--3.398)0.989 (0.835--1.171)0.899 T317362 (1.738--2.262)0.965 (0.823--1.131)0.657 T424683 (2.791--3.209)0.975 (0.833--1.141)0.749 TX3283NANANA**N Stage**0.113 N016953 (2.734--3.266)1 (reference)1 N16102 (1.608--2.392)1.077 (0.976--1.188)0.142 N233382 (1.799--2.201)1.084 (1.018--1.155)0.012 N317183 (2.706--3.294)1.029 (0.957--1.107)0.443 NX1593NANANA**Brain Met**0.071 Yes17332 (1.770--2.230)1 (reference)1 None66783 (2.863--3.137)0.936 (0.884--0.992)0.025 Unknown543NANANA**Liver Met**\<0.001 Yes29852 (1.835--2.165)1 (reference)1 None54733 (2.836--3.164)0.760 (0.723--0.798)\<0.001 Unknown496NANANA[^2]

3.2. Risk factors for developing bone metastasis {#sec0007}
------------------------------------------------

As shown in [Table 1](#tbl0001){ref-type="table"}, the possibility of BM at diagnosis were significantly associated with male, younger age, adenocarcinoma, poor tumor differentiation grade, higher N stage(N3), brain metastasis and liver metastasis, while the tumor size was demonstrated not to be an independent risk factor. In addition, there was no difference between T0 and higher T stage, but patients with T1 showed less chance of BM.

3.3. Survival and prognostic factors for BM {#sec0008}
-------------------------------------------

Vital prognostic factors selected by sex ([Fig. 2](#fig0002){ref-type="fig"}A), age ([Fig. 2](#fig0002){ref-type="fig"}B), race ([Fig. 2](#fig0002){ref-type="fig"}C), marital status ([Fig. 2](#fig0002){ref-type="fig"}D), pathologic type ([Fig. 2](#fig0002){ref-type="fig"}E) and liver metastasis ([Fig. 2](#fig0002){ref-type="fig"}F) were graphically displayed.Fig. 2Kaplan--Meier analysis of overall survival among lung cancer patients with bone metastasis were displayed by sex (A), age (B), race (C), marital status (D), pathologic type (E) and liver metastasis (F).**Abbreviations:** AI, American Indian/Alaska Native; API, Asian or Pacific Islander; Met, metastasis; AD, adenocarcinoma; SQCC, squamouscell carcinoma; LCLC, large cell carcinoma; SCLC, small cell carcinoma.Fig 2

AS shown in [Table 2](#tbl0002){ref-type="table"}, the prognostic factors for BM in lung cancer patients were observed clearly. In the multivariate Cox regression model, patients of male, older age, unmarried status, large cell carcinoma, squamouscell carcinoma, metastasis at liver were correlated with higher risk of poor prognosis. Grade, T stage, N stage and brain metastasis were not significantly correlated with survival. Although the tumor size was also an independent prognostic factor, the larger tumor size resulting in the worse the outcome was not observed. Patients with BM in Asian or Pacific Islander (PAI) displayed the better outcome, while there was no difference among other races on survival.

In our study, the homogeneous risk factors for the odds and prognosis of BM in lung cancer patients were male and metastasis at liver ([Fig. 3](#fig0003){ref-type="fig"}). However, younger age, married status, poor tumor differentiation grade, higher T stage, higher N stage, metastasis at brain were all positively correlated with the development of BM but they were not the prognostic factors of BM. Older age and unmarried status both cause the worse survival of patients with BM but not influenced the occurrence of BM. Meanwhile, adenocarcinoma was prone to be the most risk factors for the occurrence of BM in different pathologic types, but did not cause the worst prognosis.Fig. 3The homogeneous and heterogeneous risk factors and prognosis factor of BM in patients with lung cancer.**Abbreviation:** BM, bone metastases; API, Asian or Pacific Islander; SQCC, squamous cell carcinoma; LCLC, large cell carcinoma.Fig 3

4. Discussion {#sec0009}
=============

Based on the SEER database, we found that the amount of BM in lung cancer patients was staggering, accounting for 25.89%. In addition, BM morbidity still might be underestimated for ineligible cases. Therefore, it is vital to estimate the risk factors for patients in lung cancer and the prognosis for patients diagnosed with BM. Previously, only some small sample size has been used to estimate the prognosis of BM [@bib0017], [@bib0018]. Li Zhang et al. and Sugiura et al. only retrospectively observed 168 and 118 patients with BM and discussed the prognostic factors, respectively. In the large population-based cohort study, larger cases were carried out to analyze and predict the prognosis. In the study, we observed a number of lung cancer patients whose survival time is less than two months, and the dismal median survival of lung cancer with BM observed was lower than previous reports [@bib0017], [@bib0019]. This was not difficult to understand that lots of patients with lung cancer were not willing to accept treatment in hospital and chose natural death because of the poor physical state, so the part of cases might be missed and not be included in the previous literatures. However, based on the reliable and large data from SEER program, the survival time obtained from this study could reflect the real length of life of cancer patients.

A number of risk factors of BM development in lung cancer patients were found, including male, younger age, adenocarcinoma, poor tumor differentiation grade, higher N stage, metastasis at brain and metastasis at liver. Thus, doctors should pay more attention to these risk factors for their lung cancer patients. Furthermore, a skeletal scanning should be advised timely for their patients with these risk factors. In the future, the risk factors might be considered to be predictive factors of BM for lung cancer patients.

A number of prognostic factors of BM in lung cancer patients were correlated with male, older age, large cell carcinoma, squamouscell carcinoma, unmarried status, metastasis at liver and the tumor size. It was surprising that grade, T and N stage were able to confirm the prognosis of BM. Based on the above prognostic factors in the study, doctors might be capable of making a prognostic estimation and clinical guidelines for the lung cancer patients with BM effectively.

In our study, male carried a higher risk for the development of BM and poorer prognosis in lung cancer patients with BM. A previous study have shown that the median survival time did make the difference between two genders in lung cancer with bone metastasis; for male patients was 7.9 months, versus 13 months in female [@bib0017]. Male has been shown to portend poor survival in that study, and the difference was demonstrated to be statistically significant in our larger cohort study. We suspect that this phenomenon may be related to smoking and social stress in men, but we can\'t capture some basic information in the database.

Adenocarcinoma was considered to be the highest risk factors of BM development as a kind of pathologic type. To our knowledge, this is the first report to identify the risk factor at the time of diagnosis of BM. However, the prognosis of BM with large cell carcinoma or squamouscell carcinoma becomes worse than adenocarcinoma. The previous study by Sugiura et al. has reported that the patients of BM with nonadenocarcinoma had a worse prognosis, while those with adenocarcinoma alone had the favorable prognosis, which was consistent with our finding [@bib0017].

In addition, black race compared with whites were not found to have a higher risk of development and prognosis of BM, while PAI had the best outcome. As we all known, race diversity in cancer patients have been still existing and black men have higher cancer rates than other races. Probably, blacks were diagnosed with more advanced cancers than other races in the US [@bib0020]. In a latest report, the five-year survival of blacks was lower than whites for most cancers, but the disparity has been narrowed in men which can explain our founding to some extent [@bib0021]. Anyway, in our study, race diversity is not only a risk factor for the occurrence of BM, but also a risk factor for the prognosis of patients with BM. Therefore, racial disparities must be focused efforts on reducing.

Lung cancer with liver metastasis or brain metastasis continues to have a poor prognosis despite recent advances in medical level [@bib0022], [@bib0023], [@bib0024], [@bib0025], [@bib0026], [@bib0027]. Interestingly, BM patients with liver metastasis had a worse prognosis, but the presence or absence of brain metastasis did not affect survival. Because brain metastasis was not, like liver metastasis, significantly associated with the survival of lung cancer with BM, oncologists could try to conversely evaluate the risks of BM and/or liver metastasis on lung cancer with brain metastasis. Alternatively, they could evaluate the risks of brain metastasis and/or BM on lung cancer with liver metastasis. By doing these, they may hopefully identify factors which prolong patients\' survival significantly longer than those identified by us in our manuscript. Similarly, younger people with lung cancer is more likely to have BM, but older patients with BM have a worse prognosis. The poorer prognosis related to age in non-small cell lung cancer with bone metastasis have been observed by Bae et al. [@bib0028]. Since unmarried status has a serious impact on the prognosis of patients with BM, we advocated maintaining a good marriage which could extend the life span of patients.

These astonishing discoveries deserved further analysis and exploration by medical researchers for the unclear causes. As mentioned above, it would be important that physicians must pay more attention to the heterogeneous risk factors for occurrence and prognostic of BM in patients with lung cancer. Based on our research, further studies looking into the potential explanations on the heterogeneous and heterogeneous risk factors were needed.

Except for the intention of estimating the risk factors, the other significance of this research related to the factors was the finding of cancer care and management. Even if, most of the factors, except age, associated with improved prognosis of lung cancer patients with BM only averagely prolong patients\' survival for one month. But significant, it seemed that one month survival clinically also impacted and benefited patients too much on account of the poor prognosis. Furthermore, based on several meaningful risk factors observed in our study, patients\' survival might be more different in the process of clinical evaluation or intervention. At the same time, we acknowledged that the difference of the possibility of BM or the survival time would be more significant through interfering with these factors, if we collected the cancer patient whose survival time was more than one year. However, oncologists were not able to recognize the accurate life span, so we considered that all lung cancer patients with adequate information initially diagnosed should be included.

Of course, several limitations existed in the present study. Firstly, a certain number of patients with incomplete and invalid information were excluded. Secondly, we can\'t research some basic information in the SEER database which could had an impact on patients, such as smoking, Body Mass Index, family history. Thirdly, several selection bias might exist in the retrospective trial.

5. Conclusion {#sec0010}
=============

In this study, we estimated the risk factors for occurrence and prognosis of lung cancer patients with BM in an effort to provide some information for making a potential treatment plan and clinical evaluation. In addition, there were two homogeneous risk factors and a number of heterogeneous factors, which deserved our attention.
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